BJH - volume 3, issue 3, september 2012
S. Simoens PhD, MSc
Anticoagulants reduce blood clotting and are effective in preventing and treating venous thromboembolism, stroke and myocardial infarction. New oral agents such as dabigatran and rivaroxaban have recently been approved for these indications. Dabigatran and rivaroxaban benefit from oral administration, but have a higher potential for drug interactions than low molecular weight heparins. As compared with warfarin, dabigatran and rivaroxaban have a rapid onset of action and a predictable anticoagulant effect, obviating the need for routine coagulation monitoring. Although there are few economic evaluations of anticoagulants, the existing evidence suggests that the cost-effectiveness of anticoagulants depends on the alternative with which the anticoagulant is compared and on the specific disease.
(BELG J HEMATOL 2012;3:82–87)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
